Michael W Deininger
Overview
Explore the profile of Michael W Deininger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
7537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cruz-Rodriguez N, Deininger M
Blood
. 2024 Dec;
145(9):931-943.
PMID: 39729529
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care...
2.
Van Scoyk A, Antelope O, Ayer D, Peterson R, Pomicter A, Owen S, et al.
Cell Chem Biol
. 2024 Nov;
31(11):2002-2014.e4.
PMID: 39515338
Lysine acylation can direct protein function, localization, and interactions. Sirtuins deacylate lysine toward maintaining cellular homeostasis, and their aberrant expression contributes to the pathogenesis of multiple conditions, including cancer. Measuring...
3.
Huang X, Pomicter A, Ahmann J, Qiao Y, Chen O, George T, et al.
Blood Cancer J
. 2024 Oct;
14(1):179.
PMID: 39402020
No abstract available.
4.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
5.
Qiao Y, Huang X, Moos P, Ahmann J, Pomicter A, Deininger M, et al.
Genome Res
. 2024 Jan;
34(1):94-105.
PMID: 38195207
Genetic and gene expression heterogeneity is an essential hallmark of many tumors, allowing the cancer to evolve and to develop resistance to treatment. Currently, the most commonly used data types...
6.
Han H, Kim J, Pyne D, Travas A, Ambalavanan A, Kimura S, et al.
Leukemia
. 2023 Dec;
38(2):412-415.
PMID: 38155246
No abstract available.
7.
Kantner D, Megill E, Bostwick A, Yang V, Bekeova C, Van Scoyk A, et al.
Anal Biochem
. 2023 Nov;
685:115405.
PMID: 38016493
Acetyl-Coenzyme A is a central metabolite in catabolic and anabolic pathways as well as the acyl donor for acetylation reactions. Multiple quantitative measurement techniques for acetyl-CoA have been reported, including...
8.
Tashi T, Deininger M
Immunol Allergy Clin North Am
. 2023 Sep;
43(4):723-741.
PMID: 37758409
Advanced systemic mastocytosis (AdvSM) is a heterogeneous group of disorders characterized by neoplastic mast cell-related organ damage and frequently associated with a myeloid neoplasm. The 3 clinical entities that comprise...
9.
Van Scoyk A, Antelope O, Franzini A, Ayer D, Peterson R, Pomicter A, et al.
bioRxiv
. 2023 Aug;
PMID: 37645727
Lysine acylation can direct protein function, localization, and interactions. Sirtuins deacylate lysine towards maintaining cellular homeostasis, and their aberrant expression contributes to the pathogenesis of multiple pathological conditions, including cancer....
10.
Garrett M, Knight B, Cortes J, Deininger M
Cancer Med
. 2023 Aug;
12(17):17981-17992.
PMID: 37553873
Background: The BELA and BFORE trials compared bosutinib starting doses of 500 mg once daily (QD) and 400 mg QD, respectively, with imatinib in adults with newly diagnosed chronic phase...